Novel multifunctional nanoliposomes inhibit α-synuclein fibrillization, attenuate microglial activation, and silence the expression of SNCA gene

Hoppe, 2021, α-Synuclein strains: does amyloid conformation explain the heterogeneity of synucleinopathies?, Biomolecules, 11, 931, 10.3390/biom11070931 Outeiro, 2021 Murray, 2001, Synucleinopathies: a pathological and molecular review, Clin Neurosci Res, 1, 445, 10.1016/S1566-2772(01)00023-8 Uversky, 2007, Neuropathology, biochemistry, and biophysics of α-synuclein aggregation, J Neurochem, 103, 17, 10.1111/j.1471-4159.2007.04764.x Kumar, 2018, Cytotoxic oligomers and fibrils trapped in a gel-like state of α-synuclein assemblies, Angew Chem, 130, 5360, 10.1002/ange.201711854 Rogers, 2007, Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?, Int Rev Neurobiol, 82, 235, 10.1016/S0074-7742(07)82012-5 Theodore, 2008, Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease, J Neuropathol Exp Neurol, 67, 1149, 10.1097/NEN.0b013e31818e5e99 Ugalde, 2016, Pathogenic mechanisms of prion protein, amyloid β and α synuclein misfolding: the prion concept and neurotoxicity of protein oligomers, J Neurochem, 139, 162, 10.1111/jnc.13772 Muñoz-Fernández, 1998, The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system, Prog Neurobiol, 56, 307, 10.1016/S0301-0082(98)00045-8 Wong, 2017, α-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies, Nat Med, 23, 1, 10.1038/nm.4269 Zhao, 2020, Antioxidant nanoparticles for concerted inhibition of α-synuclein fibrillization, and attenuation of microglial intracellular aggregation and activation, Front Bioeng Biotechnol, 8, 112, 10.3389/fbioe.2020.00112 Aliakbari, 2018, The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's disease, Nanoscale, 10, 9174, 10.1039/C8NR00632F Ruotolo, 2020, Cerium oxide nanoparticles rescue α-synuclein-induced toxicity in a yeast model of Parkinson's disease, Nanomaterials, 10, 235, 10.3390/nano10020235 Álvarez, 2013, Influence of gold nanoparticles on the kinetics of α-synuclein aggregation, Nano Lett, 13, 6156, 10.1021/nl403490e Jebali, 2020, Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils, J Neuroimmunol, 347, 577352, 10.1016/j.jneuroim.2020.577352 Cortesi, 1999, Preparation of liposomes by reverse-phase evaporation using alternative organic solvents, J Microencapsulation, 16, 251, 10.1080/026520499289220 Vicente Miranda, 2017, Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies, Brain, 140, 1399, 10.1093/brain/awx056 Lull, 2010, Microglial activation and chronic neurodegeneration, Neurotherapeutics, 7, 354, 10.1016/j.nurt.2010.05.014 Duda, 2000, Neuropathology of synuclein aggregates: new insights into mechanisms of neurodegenerative diseases, J Neurosci Res, 61, 121, 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4 Winner, 2011, In vivo demonstration that α-synuclein oligomers are toxic, Proc Natl Acad Sci, 108, 4194, 10.1073/pnas.1100976108 Gustot, 2015, Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease, Biochem J, 471, 323, 10.1042/BJ20150617 Shaltiel-Karyo, 2013, A blood–brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD), J Biol Chem, 288, 17579, 10.1074/jbc.M112.434787 Staats, 2020, Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter, Commun Chem, 3, 1, 10.1038/s42004-020-00412-y Giacobbe, 2020, The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative and neurological disorders, Front Psychiatry, 11, 122, 10.3389/fpsyt.2020.00122 Uehara, 2019, Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease, Sci Rep, 9, 1, 10.1038/s41598-019-43772-9